Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy

Cancer

Volumn 117, Issue 9, 2011, Pages 1917-1927

  Lyman, Gary H ^a,c   Kuderer, Nicole M ^a   Crawford, Jeffrey ^a   Wolff, Debra A ^a   Culakova, Eva ^a   Poniewierski, Marek S ^a   Dale, David C ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c DUKE CANCER INSTITUTE   (United States)

Author keywords

chemotherapy; febrile neutropenia; neutropenia; risk model

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALKYLATING AGENT; ANTHRACYCLINE; COLONY STIMULATING FACTOR; DNA TOPOISOMERASE INHIBITOR; GEMCITABINE; GYRASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; NAVELBINE; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CAUCASIAN; COHORT ANALYSIS; COLORECTAL CANCER; FEBRILE NEUTROPENIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SOLID TUMOR;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NEUTROPENIA; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 79955430154     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25691     Document Type: Article

References (29)

1. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106: 2258-2266. (Pubitemid 43673249)
2. Lyman GH, Dale DC, Crawford J,. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003; 21: 4524-4531. (Pubitemid 46594022)
3. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004; 22: 4302-4311. (Pubitemid 41185151)
4. Lyman GH,. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009; 7: 99-108.
5. Shayne M, Culakova E, Wolff D, et al. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer. 2009; 115: 5319-5328.
6. Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007; 110: 1611-1620. (Pubitemid 47463077)
7. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003; 44: 2069-2076. (Pubitemid 37369646)
8. Lyman GH, Delgado DJ,. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003; 98: 2402-2409. (Pubitemid 37466655)
9. Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008; 6: 109-118. (Pubitemid 351340522)
10. Lyman GH,. Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology (Williston Park). 2003; 17: 8-13.
11. Dale D, Crawford J, Lyman GH,. Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices from Randomized Clinical Trials. J Natl Compr Canc Netw. 2003; 1: 440-454.
12. Lyman GH, Lyman CH, Agboola O,. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005; 10: 427-437. (Pubitemid 40993570)
13. Balducci L, Hardy CL, Lyman GH,. Hematopoietic growth factors in the older cancer patient. Curr Opin Hematol. 2001; 8: 170-187. (Pubitemid 32328131)
14. Shayne M, Crawford J, Dale DC, et al. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006; 100: 255-262. (Pubitemid 44707919)
15. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
16. Molinaro AM, Simon R, Pfeiffer RM,. Prediction error estimation: a comparison of resampling methods. Bioinformatics. 2005; 21: 3301-3307. (Pubitemid 41418445)
17. Perneger TV,. What's wrong with Bonferroni adjustments. BMJ. 1998; 316: 1236-1238. (Pubitemid 28171344)
18. Rothman KJ,. No adjustments are needed for multiple comparisons. Epidemiology. 1990; 1: 43-46. (Pubitemid 20255621)
19. Gerds TA, Cai T, Schumacher M,. The performance of risk prediction models. Biom J. 2008; 50: 457-479.
20. Nagelkerke NJD,. A note on a general definition of the coefficient of determination. Biometrika. 1991; 78: 691-692.
21. Jenkins P, Freeman S,. Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol. 2009; 20: 34-40.
22. Moreau M, Klastersky J, Schwarzbold A, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol. 2009; 20: 513-519.
23. Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol. 2009; 144: 677-685.
24. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991; 325: 164-170.
25. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007; 25: 3158-3167. (Pubitemid 47218066)
26. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24: 3187-3205. (Pubitemid 46638957)
27. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006; 42: 2433-2453. (Pubitemid 44442936)
28. Crawford J, Armitage J, Balducci L, et al. Myeloid growth factors. J Natl Compr Canc Netw. 2009; 7: 64-83.
29. Lyman GH, Kleiner JM,. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. J Natl Compr Canc Netw. 2007; 5: 217-228. (Pubitemid 46423060)